Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition

Tumori

Volumn 92, Issue 5, 2006, Pages 379-383

  Beretta, Elena ^a   Di Bartolomeo, Maria ^a   Buzzoni, Roberto ^a   Ferrario, Erminia ^a   Mariani, Luigi ^a   Gevorgyan, Arpine ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adenocarcinoma; Chemotherapy; Fluorouracil; Irinotecan; Metastatic gastric cancer

Indexed keywords

ATROPINE; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PEMETREXED; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 33845289437     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200502     Document Type: Article

References (25)

1. National Comprehensive Cancer Network Proceedings: NC-CN practice guidelines for upper gastrointestinal carcinomas. Oncology, 12: 179-223, 1998.
2. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8: 163-168, 1997.
3. Murad A, Santiago F, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer, 72: 37-41, 1993.
4. Pyrhonene S, Kuitunen T, Kouri M: A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Ann Oncol, 3 (suppl 5): abstr 47, 1992.
5. Wils J, Bleiberg H: Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol, 25: 3-8, 1989.
6. Loehrer PJ Sr, Harry D, Chlebowski RT: 5-fluorouracil vs epirubicin vs 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest New Drugs, 12: 57-63, 1994.
7. Cunningham D, Soukop M, McArdle CS, Carter DC, Smyth JF, Allan SG, Kaye SB, Sangster G, Calman KC: Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. Br J Surg, 71: 673-676, 1984.
8. Haim N, Cohen Y, Honigman J, Robinson E: Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin and mitomycin-C (FAM). Cancer Chemother Pharmacol, 8: 277-280, 1982.
9. Haim N, Epelbaum R, Cohen Y, Robinson E: Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin (doxorubicin) and mitomycin C (modified FAM). Cancer, 54: 1999-2002, 1984.
10. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9: 827-831, 1991.
11. Bajetta E, Di Bartolomeo M, De Braud F, Bozzetti F, Bochicchio AM, Comella P, Fagnani D, Farina G, Ferroni C: Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicenter study of the Italian Trials in Medical Oncology (ITMO) Group. Eur J Cancer, 30A: 596-600, 1994.
12. Di Bartolomeo M, Bajetta E, De Braud F, Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G, Cozzaglio L: Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology, 52: 41-44, 1995.
13. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer, 72: 37-41, 1993.
14. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15: 261-267, 1997.
15. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Orgnization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 18: 2648-2657, 2000.
16. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E: Irinotecan in combination with 5-fluorouracil and folinic acid or cisplatin in patients with advanced gastric cancer or esophageal-gastric junction adenocarcinoma: results of a randomised phase II study. Ann Oncol, 15: 1773-1781, 2004.
17. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol, 17: 319-323, 1999.
18. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Awad L: Randomized phase III trial of irinotecan + 5FU/FA vs CDDP+5FU in first-line advanced gastric cancer patients. Proc ASCO, 23: 308s, 4003 (abstr), 2005.
19. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma. Results of a phase II study. Cancer, 94: 641-646, 2002.
20. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL: A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol, 12: 1575-1580, 2001.
21. Moehler M, Haas U, Siebler J, Schimanski C, Hertkorn C, Hoehler T, Galle PR, Heike M: Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (IFL) in patients with advanced gastric cancer. Anticancer Drugs, 14: 645-650, 2003.
22. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M: Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer, 89: 997-1001, 2003.
23. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol, 15: 64-69, 2004.
24. Yoshioka T, Sakata Y, Terashima M, Sekikawa K, Gamoh M, Mitachi Y, Saitoh S, Kanamaru R: Biweekly administration regimen of docetaxel combined with CPT11 in patients with inoperable or recurrent gastric cancer. Gastric Cancer, 6: 153-158, 2003.
25. Bouchè O, Raoul JL, Bonnetain F, Giovannini M: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol, 21: 4319-4328, 2004.